PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Reproductive Control Agents”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 685 records · Page 38Linked to original sources
PubMed1985

Dysfunctional uterine bleeding in ovulatory women.

Ovulatory dysfunctional uterine bleeding (DUB), a disease prevalent in the latter half of the reproductive years, is diagnosed when organic causes for bleeding have been excluded by clinical, laboratory, and surgical diagnostic means. Disordered prostaglandin metabolism within the endometrium explains most cases of DUB. Nonsteroidal antiinflammatory drugs, oral contraceptives, and oral progestin are effective medical alternatives for women who wish to retain their uterus or to avoid surgery. Hysterectomy is a rapid cure for DUB and is a therapy that is acceptable to many, if not most, women.

Adult↗
PubMed1982

The effects of ampicillin on oral contraceptive steroids in women.

1 Thirteen women taking long term oral contraceptive steroids were studied while taking ampicillin (500 mg three times daily) and compared to a control cycle while not taking ampicillin. 2 There were no significant changes in the plasma concentrations of ethinyloestradiol, levonorgestrel, follicle stimulating hormone or progesterone, although lower concentrations of ethinyloestradiol were noted in two women. 3 We conclude that most patients taking oral contraceptive steroids do not need to take alternative contraceptive precautions while taking ampicillin.

Adult↗
PubMed1988

Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.

Eight men (experiment 1) requesting male contraception received a daily oral dose of 20 mg medroxyprogesterone acetate (MPA) combined with 125 mg percutaneous dihydrotestosterone (DHT). Three months later the mean sperm count was only diminished slightly; the replacement of DHT for four men by percutaneous testosterone at the same concentration led to a dramatic fall in sperm count. For 6-18 months all men were treated with MPA plus percutaneous testosterone (250 mg daily). The latter dose restored physiological levels of plasma testosterone. Follicle-stimulating hormone levels were inhibited more severely than in the DHT-treated group, whereas LH levels were variable. Azoospermia was achieved and maintained in six cases; two men were oligozoospermic and in one case a moderate secondary rise in the sperm count was observed. Twelve volunteers (experiment 2) received a daily oral dose of either 5 or 10 mg norethisterone acetate plus percutaneous testosterone (250 mg daily). All of them achieved azoospermia within 2 months, but two subjects later exhibited a partial restoration in sperm count. Follicle-stimulating hormone and LH levels were inhibited more severely than in the first experiment. The sperm count and gonadotrophin levels returned to initial values within 6 months after cessation of the treatment in both experiments. No side-effects were noted concerning blood parameters, libido or body weight. However, several female partners had elevated levels of plasma testosterone. In experiment 3 (13 volunteers), percutaneous testosterone was replaced by oral testosterone undecanoate (160 mg daily). Only seven men were azoospermic and most of them had lowered levels of plasma testosterone. Thus, the combination of percutaneous testosterone and oral progestagens appears to be the most convenient for male hormonal contraception.

Administration, Cutaneous↗
PubMed1982

Forces required for surgical dilatation of the pregnant and non-pregnant human cervix.

The force required to dilate the uterine cervix to a diameter of 8 mm has been measured in 200 non-pregnant and 40 early pregnant patients. In general, the resistance offered by the cervix was lower in parous than in nulliparous subjects and in pregnant compared with non-pregnant subjects. The phase of the menstrual cycle did not appear to influence cervical resistance but the highest recordings were seen in postmenopausal subjects. Particularly low resistance was encountered in women receiving Depo-Provera for contraceptive purposes.

Cervix Uteri↗
PubMed1983

Effects of continuous levonorgestrel treatment (subcutaneous capsules) on the lipoprotein and carbohydrate metabolism in fertile women.

The lipoprotein and carbohydrate metabolism was studied during contraceptive treatment with levonorgestrel, released at a low rate (70 micrograms/day) from subcutaneous capsules, in five women who were treated for 180-403 days. The serum cholesterol concentration decreased slightly but significantly during treatment. This was attributable to a tendency to a reduction of cholesterol in high-density lipoproteins. The treatment did not affect the lipoprotein lipase activity in adipose tissue. The elimination rates of intravenously injected fat and glucose were unchanged, as were the serum insulin concentrations. Thus, in this pilot study the concentration and composition of the serum lipoproteins altered to only a minor extent during treatment with levonorgestrel in a dose of 70 micrograms/day.

Adult↗
PubMed1986

The diurnal increase in euglobulin fibrinolytic activity in women using oral contraceptives and in normal women, and the generation of intrinsic fibrinolytic activity.

The diurnal fluctuations in plasma euglobulin fibrinolytic activity in women on oral contraceptives and in normal women showed similar patterns of increase. Following inactivation of inhibitors by flufenamate the individual increases and the evening levels did not differ. The diurnal increase was related to an increase in extrinsic (tissue-type) plasminogen activator (t-PA) activity, which contributes little to the total activity of the euglobulin fraction but induces an activation of the intrinsic system.

Adult↗
PubMedDate not supplied

Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices.

The effectiveness of a new levo-norgestrel releasing intrauterine device is assessed in fourteen patients with histologically confirmed hyperplastic lesions of the endometrial mucosa. The morphologic response of the hyperplastic endometria to the action of the levo-norgestrel in this study explains the regression of the cases so treated.

Adult↗
PubMed1986

[Male contraception].

Explore the source record for details and available documents.

Contraceptive Agents, Male↗
PubMedDate not supplied

Cytologic findings in oral contraceptive users among Israeli Jewish women.

A group of 3,317 Jewish Israeli women were studied to evaluate a possible correlation between previous and recent oral contraceptive usage and cervical cytopathologic findings in Papanicolaou smears. A positive correlation was established between oral contraceptive usage and the occurrence of inflammatory findings: the rate of inflammatory changes depended on the length of usage, with a time lapse of at least one year preceding the appearance of such inflammatory changes. The cessation of oral contraceptive usage was associated with a decrease in the rate of inflammatory findings. No cases of cervical intraepithelial neoplasia or malignancy were found.

Adolescent↗
PubMed1983

The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?

In 1978, the Food and Drug Administration denied approval of the three-month injectable contraceptive depot medroxyprogesterone acetate for use in the United States. This decision goes against the advice of the FDA's own scientific advisory panels, as well as the rulings of the World Health Organization and the drug regulation institutions of more than 70 developed and developing countries. In response to protest from the manufacturer of depot medroxyprogesterone acetate and from many health professionals, the FDA took the unusual step of scheduling a public board of inquiry to review its decision in January 1983. Reviewing the scientific literature on the risks and benefits of depot medroxyprogesterone acetate, we find no reason to deny depot medroxyprogesterone acetate approval, provided that studies of its possible side effects are continued and that women use it only after having made an informed choice between this and other methods of contraception.

Delayed-Action Preparations↗